Download full-text PDF |
Source |
---|
Gels
December 2024
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
Fungal keratitis is a severe ocular infection caused by pathogenic fungi, leading to potential vision loss if untreated. Current antifungal treatments face limitations such as low solubility, poor corneal penetration, and limited therapeutic options. This study aimed to develop a thermosensitive in situ gel incorporating ketoconazole nanoparticles (NPs) to enhance drug solubility, stability, and antifungal activity.
View Article and Find Full Text PDFBMC Health Serv Res
January 2025
Department of Pharmaceutics and Social Pharmacy, School of Pharmacy, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia.
Background: Extemporaneous compounding for dermatological use is an important therapeutic alternative for patients whose clinical needs are not met by approved drug products circulated in the market. Evaluating patients' perceptions and levels of satisfaction towards such services is an important factor for the adherence of patients and maintaining the quality of healthcare services. The current study aimed to assess patients' perception and level of satisfaction with the compounding service and extemporaneous preparations rendered at ALERT hospital.
View Article and Find Full Text PDFEur J Pharm Sci
January 2025
Pharmaceutical Sciences Laboratory, Science and Engineering, Åbo Akademi University, BioCity, Tykistökatu 6A, Turku FI-20520, Finland; CurifyLabs Oy, Salmisaarenaukio 1, Helsinki FI-00180, Finland.
The exploration of three-dimensional (3D) printing inspired technologies in pharmaceutical compounding reveals a promising frontier in personalized medicine manufacture. This study focuses on the development of clopidogrel bisulphate tablets, with doses ranging from 2 mg to 20 mg per tablet, suitable for pediatric use. The study explored a semi-solid extrusion-based deposition technology already being used in compounding pharmacies across several European locations.
View Article and Find Full Text PDFInt J Pharm Compd
August 2024
College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana.
Clonidine Hydrochloride is a centrally acting alpha-agonist hypotensive agent available as tablets for oral administration in three dosage strengths: 0.1 mg, 0.2 mg and 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!